Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Holding(s) in Company

23 Jan 2019 17:38

RNS Number : 9352N
Futura Medical PLC
23 January 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Futura Medical PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Lombard Odier Asset Management (Europe) Limited

City and country of registered office (if applicable)

London, United-Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

Disclosure on behalf of accounts managed on a discretionary basis by Lombard Odier Investment Managers group.

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

22/01/2019

6. Date on which issuer notified (DD/MM/YYYY):

23/01/2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

21.79%

21.79%

204,660,267.00

Position of previous notification (if

applicable)

22.96%

22.96%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0033278473

44,455,631

21.72%

SUBTOTAL 8. A

44,455,631

21.72%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London, United-Kingdom

Date of completion

23/01/2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEAXFDADXNEFF
Date   Source Headline
17th Jul 20237:00 amRNSFutura/Haleon Enter US Commercialisation Agreement
30th Jun 20237:00 amRNSFutura Medical - Total Voting Rights
23rd Jun 20234:30 pmRNSRecording of Investor Seminar
22nd Jun 20233:19 pmRNSFutura Medical Annual General Meeting Results
22nd Jun 20237:00 amRNSFutura Medical AGM Statement
19th Jun 202310:25 amRNSCorrection - TR-1: Notification of major holdings
16th Jun 20234:05 pmRNSTR-1: Notification of major holdings
12th Jun 20238:23 amRNSExercise of Warrants
12th Jun 20237:00 amRNSMED3000 Granted US FDA Approval for OTC Sale
8th Jun 20237:00 amRNSFutura Medical Announces Investor Seminar
31st May 20237:00 amRNSBlock Listing Six Monthly Return
26th May 20237:00 amRNSNotice of AGM and availability of Annual Report
24th Apr 20237:00 amRNSTR-1: Notification of major holdings
18th Apr 20237:00 amRNSMED3000, Eroxon® UK Launch
6th Apr 202311:03 amRNSDirectors' / PDMR Dealing and Grant of Options
5th Apr 20237:00 amRNSFull Year Results ended 31 December 2022
29th Mar 20237:00 amRNSUpdate on MED3000 regulatory approval in the US
27th Mar 20235:24 pmRNSNotice of Preliminary Results 2022
14th Mar 20238:33 amRNSMED3000 commercial and US regulatory update
15th Feb 20237:00 amRNSMED3000 FM71 Presentation at ESSM Congress 2023
1st Feb 20231:26 pmRNSBlock Listing Applications to AIM
26th Jan 20237:00 amRNSPre-launch of MED3000 ahead of H1 2023 launch
12th Jan 202311:09 amRNSFutura Remuneration, Options & Total Voting Rights
15th Dec 20223:01 pmRNSTR-1: Notification of major holdings
13th Dec 20221:10 pmEQSFutura Medical 'on track' for launch in H1 2023
13th Dec 20227:00 amRNSFutura Medical announce milestone year for MED3000
30th Nov 20227:00 amRNSFutura Block Listing Six Monthly Return
30th Nov 20227:00 amRNSTotal Voting Rights
21st Oct 20224:40 pmRNSSecond Price Monitoring Extn
21st Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 202212:25 pmRNSTR-1: Notification of major holdings
4th Oct 20225:31 pmRNSTotal Voting Rights
3rd Oct 20227:00 amRNSApplication to the US FDA for MED3000
16th Sep 20229:57 amRNSPDMR Dealing and Total Voting Rights
13th Sep 20227:00 amRNSFutura Medical Interim Results 2022
1st Sep 20227:00 amRNSNotice of Interim Results
31st Aug 20227:00 amRNSHighly positive FM71 Phase 3 Study Results
12th Jul 20224:41 pmRNSSecond Price Monitoring Extn
12th Jul 20224:35 pmRNSPrice Monitoring Extension
28th Jun 20223:58 pmRNSFutura Medical AGM Results
28th Jun 20227:00 amRNSFutura Medical AGM Statement
7th Jun 20221:33 pmRNSTR-1: Notification of major holdings
1st Jun 20227:00 amRNSNotice of AGM and Availability of Annual Report
31st May 20227:00 amRNSBlock Listing Six Monthly Return
24th May 202211:40 amRNSTR-1: Notification of major holdings
23rd May 202210:35 amRNSAgreement with Cooper Consumer Health - Correction
23rd May 20227:00 amRNSMED3000 Collaboration in EEA, UK & Switzerland
17th May 20223:56 pmRNSTR-1: Notification of major holdings
16th May 20222:51 pmRNSTR-1: Notification of major holdings
13th May 202212:12 pmRNSTR-1: Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.